A Phase 3 interventional study of Sitagliptin and Metformin in Diabetes Mellitus and Type 2 Diabetes, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-09-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 72nd largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 74 in phase 3, and was the 111th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 16 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 84th largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2012, is one of 86 in phase 3, and was the 124th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the safety of the addition of sitagliptin, and its effect on hemoglobin A1c (A1C) in pediatric participants 10-17 years of age with type 2 diabetes mellitus (T2DM) with inadequate glycemic control. The primary hypothesis for this study is that sitagliptin reduces A1C more than placebo after 20 weeks of treatment.
This trial is of approximately 56 weeks in duration, including a screening period of up to 1 week, a 1-week single-blind placebo run-in period, a 20-week placebo-controlled, double blind treatment period [Phase A] and a 34-week double-blind active controlled treatment period [Phase B] during which participants randomized to the placebo arm who have not initiated glycemic rescue therapy with metformin during Phase A will receive metformin (in a blinded manner). A telephone contact will be performed 14 days after the last dose of study medication to assess for any serious adverse events (SAEs).
Participants enrolled in the metformin and placebo/sitagliptin arms prior to implementation of Protocol Amendment 05 completed the study on their original treatment assignments.
EUPASS4468 is a follow-up, non-interventional, observational assessment of safety of participants who participated in the MK-0431-083 study for up to 5 years.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 200 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
Drug: Sitagliptin · Drug: Placebo to metformin · Drug: Glycemic Rescue 1 · Biological: Glycemic Rescue 2
Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
Drug: Metformin · Drug: Placebo to sitagliptin · Drug: Placebo to metformin · Drug: Glycemic Rescue 1 · Biological: Glycemic Rescue 2
Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
Drug: Metformin
Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
Drug: Sitagliptin · Drug: Placebo to sitagliptin · Drug: Placebo to metformin
Sitagliptin 100 mg tablet administered orally once daily
Also known as: Januvia®, Tesavel®, Xelevia®, Ristaben®, Glactiv®
Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
Also known as: Glucophage®, Metgluco®, Glycoran®
Matching placebo to sitagliptin 100 mg tablet administered orally once daily
Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.
Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
Change From Baseline in Hemoglobin A1C (A1C) at Week 20
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C.
Time frame: Baseline and Week 20
Baseline Glycated Hemoglobin (A1C) for the Placebo (Pooled) Arm
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.
Time frame: Baseline
Change From Baseline In A1C at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C from a longitudinal data analysis (LDA) model. The placebo arm in this comparison is a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The Statistical Analysis Plan (SAP) did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
Time frame: Baseline and Week 20
Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56
The number of participants experiencing ≥1 adverse event during Weeks 0-56 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to Week 56
Percentage of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)
The number of participants experiencing ≥1 adverse event during Weeks 0-56 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
Time frame: Up to Week 56
Number of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54
The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to Week 54
Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)
The percentage of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
Time frame: Up to Week 54
Change From Baseline in A1C at Week 54
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. This change from baseline reflects the Week 54 A1C minus the Week 0 A1C.
Time frame: Baseline and Week 54
Percentage of Participants With A1C at Goal (<7.0%) at Week 20
The percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).
Time frame: Week 20
Percentage of Participants With A1C at Goal (<7.0%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))
The percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
Time frame: Week 20
Percentage of Participants With A1C at Goal (<6.5%) at Week 20
The percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).
Time frame: Week 20
Percentage of Participants With A1C at Goal (<6.5%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))
The percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
Time frame: Week 20
Percentage of Participants With A1C at Goal (<7.0%) at Week 54
The percentage of participants with A1C at goal (\<7.0%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).
Time frame: Week 54
Percentage of Participants With A1C at Goal (<6.5%) at Week 54
The percentage of participants with A1C at goal (\<6.5%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).
Time frame: Week 54
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20
Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline.
Time frame: Baseline and Week 20
Baseline Fasting Plasma Glucose (FPG) for the Placebo (Pooled) Arm
Blood glucose was measured on a fasting basis. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.
Time frame: Baseline
Change From Baseline in FPG at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))
Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline and was estimated from a longitudinal data analysis model. The current outcome measure focused on results from participants randomized to sitagliptin or placebo. The Week 20 treatment comparison of Sitagliptin vs Placebo included all participants treated with Sitagliptin or Placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
Time frame: Baseline and Week 20
Change From Baseline in FPG at Week 54
Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 54 minus FPG at baseline.
Time frame: Baseline and Week 54
Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 20
PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour PMG minus the Week 0 2-hour PMG.
Time frame: Baseline and Week 20
Change From Baseline in 2-hour PMG at Week 54
PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour PMG minus the Week 0 2-hour PMG.
Time frame: Baseline and Week 54
Change From Baseline in 2-hour Incremental PMG at Week 20
2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.
Time frame: Baseline and Week 20
Change From Baseline in 2-Hour Incremental PMG at Week 54
2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.
Time frame: Baseline and Week 54
Change From Baseline in Insulin at Week 20 for Participants Not on Background Insulin
This change from baseline reflects the Week 20 insulin minus the Week 0 insulin.
Time frame: Baseline and Week 20
Change From Baseline in Insulin at Week 54 For Participants Not on Background Insulin
This change from baseline reflects the Week 54 insulin minus the Week 0 insulin.
Time frame: Baseline and Week 54
Change From Baseline in Proinsulin at Week 20 For Participants Not on Background Insulin
This change from baseline reflects the Week 20 proinsulin minus the Week 0 proinsulin.
Time frame: Baseline and Week 20
Change From Baseline in Proinsulin at Week 54 For Participants Not on Background Insulin
This change from baseline reflects the Week 54 proinsulin minus the Week 0 proinsulin.
Time frame: Baseline and Week 54
Change From Baseline in Proinsulin/Insulin Ratio at Week 20 for Participants Not on Background Insulin
Change from baseline was the Week 20 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.
Time frame: Baseline and Week 20
Change From Baseline in Proinsulin/Insulin Ratio at Week 54 For Participants Not on Background Insulin
The change from baseline was Week 54 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.
Time frame: Baseline and Week 54
Change From Baseline in Homeostatic Model Assessment of β-cell Function (HOMA-β) at Week 20 For Participants Not on Background Insulin
HOMA-β = 20 × fasting insulin (in mcIU/mL) ÷ {\[FPG (in mg/dL)/18\] - 3.5}. The change from baseline was Week 20 HOMA-β minus the Week 0 HOMA-β.
Time frame: Baseline and Week 20
Change From Baseline in HOMA-β at Week 54 For Participants Not on Background Insulin
HOMA-β = 20 × fasting insulin (in mcIU/mL) ÷ {\[FPG (in mg/dL)/18\] - 3.5}. This change from baseline was Week 54 HOMA-β minus the Week 0 HOMA-β.
Time frame: Baseline and Week 54
Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 20 For Participants Not on Background Insulin
HOMA-IR = fasting insulin (in mcIU/mL) × FPG (in mg/dL) / (22.5×18). This change from baseline was Week 20 HOMA-IR minus the Week 0 HOMA-IR.
Time frame: Baseline and Week 20
Change From Baseline in HOMA-IR at Week 54 For Participants Not on Background Insulin
HOMA-IR = fasting insulin (in mcIU/mL) × FPG (in mg/dL) / (22.5×18). This change from baseline was Week 54 HOMA-IR minus the Week 0 HOMA-IR.
Time frame: Baseline and Week 54
Change From Baseline in Glucose 3-Hour Total Area Under the Curve (AUC) at Week 20
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.
Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Insulin 3-hour AUC at Week 20
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.
Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in C-peptide 3-Hour AUC at Week 20
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.
Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Insulin 3-Hour AUC/ Glucose 3-Hour AUC Ratio at Week 20
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin total AUC/glucose total AUC ratio minus the Week 0 insulin total AUC/glucose total AUC ratio.
Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Glucose Excursion 3-Hour AUC at Week 20
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.
Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Insulin Excursion 3-Hour AUC at Week 20
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.
Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in C-peptide Excursion 3-Hour AUC at Week 20
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.
Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 20
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.
Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Glucose 3-Hour AUC at Week 54
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.
Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Insulin 3-Hour AUC at Week 54
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.
Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in C-peptide 3-Hour AUC at Week 54
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.
Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Insulin 3-Hour AUC/Glucose 3-Hour AUC Ratio at Week 54
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC/glucose 3-hour AUC ratio minus the Week 0 insulin 3-hour AUC/glucose 3-hour AUC ratio.
Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Glucose Excursion 3-Hour AUC at Week 54
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.
Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Insulin Excursion 3-Hour AUC at Week 54
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.
Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in C-Peptide Excursion 3-Hour AUC at Week 54
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.
Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 54
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.
Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20
The percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.
Time frame: Up to Week 20
Percentage of Participants Initiating Glycemic Rescue Therapy by Week 54
The percentage of participants who initiated glycemic rescue therapy prior to Week 54 was reported.
Time frame: Up to Week 54
Change From Baseline in Body Mass Index (BMI) at Week 20
This change from baseline was Week 20 BMI minus the Week 0 BMI.
Time frame: Baseline and Week 20
Change From Baseline in BMI at Week 54
This change from baseline was Week 54 BMI minus the Week 0 BMI.
Time frame: Baseline and Week 54
Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 20
The percent change from baseline in CD26 = (\[CD26 value at Week 20\] - \[baseline CD26 value\]) ÷ baseline CD26 value × 100.
Time frame: Baseline and Week 20
Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 54
The percent change from baseline in CD26 = (\[CD26 value at Week 54\] - \[baseline CD26 value\]) ÷ baseline CD26 value × 100.
Time frame: Baseline and Week 54
Change From Baseline in Calcitonin at Week 20 - Females
Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.
Time frame: Baseline and Week 20
Change From Baseline in Calcitonin at Week 54 - Females
Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.
Time frame: Baseline and Week 54
Change From Baseline in Calcitonin at Week 20 - Males
Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.
Time frame: Baseline and Week 20
Change From Baseline in Calcitonin at Week 54 - Males
Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.
Time frame: Baseline and Week 54
Change From Baseline in Urine N-terminal Cross-linking Telopeptide of Bone Collagen [u-NTx]/Creatinine Ratio at Week 20 - Females
Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents
Time frame: Baseline and Week 20
Change From Baseline u-NTx/Creatinine Ratio at Week 20 - Males
Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents
Time frame: Baseline and Week 20
Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Females
Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. Bone Collagen Equivalents
Time frame: Baseline and Week 54
Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Males
Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. All participants in the Metformin arm were missing baseline or Week 54 measurements. BCE = Bone Collagen Equivalents
Time frame: Baseline and Week 54
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Females
Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.
Time frame: Baseline and Week 20
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Females
Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.
Time frame: Baseline and Week 54
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Males
Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.
Time frame: Baseline and Week 20
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Males
Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.
Time frame: Baseline and Week 54
Percent Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) at Week 20 - Females
IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 20\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.
Time frame: Baseline and Week 20
Percent Change From Baseline in IGF-1 at Week 54 - Females
IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 54\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.
Time frame: Baseline and Week 54
Percent Change From Baseline in IGF-1 at Week 20 - Males
IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 20\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.
Time frame: Baseline and Week 20
Percent Change From Baseline in IGF-1 at Week 54 - Males
IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 54\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.
Time frame: Baseline and Week 54
Percent Change From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) at Week 20 - Females
IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 20\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.
Time frame: Baseline and Week 20
Percent Change From Baseline in IGF-BP3 at Week 54 - Females
IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 54\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.
Time frame: Baseline and Week 54
Percent Change From Baseline in IGF-BP3 at Week 20 - Males
IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 20\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.
Time frame: Baseline and Week 20
Percent Change From Baseline in IGF-BP3 at Week 54 - Males
IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 54\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.
Time frame: Baseline and Week 54
Growth Velocity at Week 20 - Females
Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).
Time frame: Week 20
Growth Velocity at Week 54 - Females
Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).
Time frame: Week 54
Growth Velocity at Week 20 - Males
Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).
Time frame: Week 20
Growth Velocity at Week 54 - Males
Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).
Time frame: Week 54
Skeletal Maturation at Week 20 - Females
Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from an X-ray of left hand and wrist.
Time frame: Week 20
Skeletal Maturation at Week 54 - Females
Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Placebo/Sitagliptin arm were missing baseline or Week 54 measurements.
Time frame: Week 54
Skeletal Maturation at Week 20 - Males
Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist.
Time frame: Week 20
Skeletal Maturation at Week 54 - Males
Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Metformin and Placebo/Sitagliptin arms were missing baseline or Week 54 measurements.
Time frame: Week 54
Change From Baseline in Tanner Staging for Genitalia at Week 20 - Males
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 20 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia.
Time frame: Baseline and Week 20
Change From Baseline in Tanner Staging for Genitalia at Week 54 - Males
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 54 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia. All participants in the Metformin arm were missing baseline or Week 54 measurements.
Time frame: Baseline and Week 54
Change From Baseline in Tanner Staging for Breasts at Week 20 - Females
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 20 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.
Time frame: Baseline and Week 20
Change From Baseline in Tanner Staging for Breasts at Week 54 - Females
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 54 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.
Time frame: Baseline and Week 54
Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Females
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.
Time frame: Baseline and Week 20
Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Females
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.
Time frame: Baseline and Week 54
Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Males
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.
Time frame: Baseline and Week 20
Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Males
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.
Time frame: Baseline and Week 54
Participants With Worsening in Dental Status at Week 20
Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 20 dental assessments versus baseline dental assessments.
Time frame: Week 20
Participants With Worsening in Dental Status at Week 54
Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 54 dental assessments versus baseline dental assessments.
Time frame: Week 54
The study recruited participants in clinics/clinical offices in 42 countries.
| Milestone | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Started | 96 | 90 | 9 | 5 |
| Completed | 95 | 90 | 9 | 5 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Not treated | 1 | 0 | 0 | 0 |
| Milestone | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Started | 95 | 90 | 9 | 5 |
| Treated | 95 | 90 | 9 | 5 |
| Completed | 85 | 86 | 8 | 5 |
| Not completed | 10 | 4 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 5 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 1 | 0 |
| Milestone | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Started | 85 | 86 | 8 | 5 |
| Completed | 74 | 78 | 6 | 5 |
| Not completed | 11 | 8 | 2 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 | 1 | 0 |
| Withdrew: Withdrawal by parent/guardian | 2 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 3 | 0 | 0 |
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C.
| Percentage | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1C (A1C) at Week 20 | -0.13 ± 1.58 | -0.02 ± 1.45 | -1.03 ± 0.72 | 0.57 ± 1.62 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.
| Percentage | Placebo (Pooled) |
|---|---|
| Baseline Glycated Hemoglobin (A1C) for the Placebo (Pooled) Arm | 7.58 ± 1.06 |
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C from a longitudinal data analysis (LDA) model. The placebo arm in this comparison is a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The Statistical Analysis Plan (SAP) did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
| Percentage | Sitagliptin | Placebo (Pooled) |
|---|---|---|
| Change From Baseline In A1C at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled)) | -0.01 (-0.35 to 0.34) | 0.18 (-0.17 to 0.53) |
The number of participants experiencing ≥1 adverse event during Weeks 0-56 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Participants | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56 | 73 | 67 | 7 | 4 |
The number of participants experiencing ≥1 adverse event during Weeks 0-56 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
| Percentage of participants | Sitagliptin | Placebo/Metformin |
|---|---|---|
| Percentage of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin) | 76.8 | 74.4 |
The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Participants | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 | 5 | 1 | 0 | 0 |
The percentage of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
| Percentage of participants | Sitagliptin | Placebo/Metformin |
|---|---|---|
| Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin) | 5.3 | 1.1 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. This change from baseline reflects the Week 54 A1C minus the Week 0 A1C.
| Percentage | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in A1C at Week 54 | -0.19 ± 1.37 | -0.90 ± 1.41 | -0.70 ± 0.94 | -0.50 ± NA |
The percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).
| Percentage of Participants | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percentage of Participants With A1C at Goal (<7.0%) at Week 20 | 49.5 | 37.8 | 77.8 | 20.0 |
The percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
| Percentage of participants | Sitagliptin | Placebo (Pooled) |
|---|---|---|
| Percentage of Participants With A1C at Goal (<7.0%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled)) | 49.5 | 36.8 |
The percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).
| Percentage of participants | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percentage of Participants With A1C at Goal (<6.5%) at Week 20 | 30.5 | 23.3 | 66.7 | 20.0 |
The percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
| Percentage of Participants | Sitagliptin | Placebo (Pooled) |
|---|---|---|
| Percentage of Participants With A1C at Goal (<6.5%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled)) | 30.5 | 23.2 |
The percentage of participants with A1C at goal (\<7.0%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).
| Percentage of participants | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percentage of Participants With A1C at Goal (<7.0%) at Week 54 | 28.4 | 40.0 | 33.3 | 20.0 |
The percentage of participants with A1C at goal (\<6.5%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).
| Percentage of participants | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percentage of Participants With A1C at Goal (<6.5%) at Week 54 | 20.0 | 35.6 | 22.2 | 20.0 |
Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline.
| mg/dL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20 | 9.98 ± 61.86 | 7.59 ± 41.11 | -19.88 ± 49.78 | 57.67 ± 51.05 |
Blood glucose was measured on a fasting basis. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.
| mg/dL | Placebo (Pooled) |
|---|---|
| Baseline Fasting Plasma Glucose (FPG) for the Placebo (Pooled) Arm | 138.8 ± 42.4 |
Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline and was estimated from a longitudinal data analysis model. The current outcome measure focused on results from participants randomized to sitagliptin or placebo. The Week 20 treatment comparison of Sitagliptin vs Placebo included all participants treated with Sitagliptin or Placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.
| mg/dL | Sitagliptin | Placebo (Pooled) |
|---|---|---|
| Change From Baseline in FPG at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled)) | 7.2 (-4.2 to 18.7) | 5.7 (-6.0 to 17.4) |
Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 54 minus FPG at baseline.
| mg/dL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in FPG at Week 54 | -3.03 ± 48.55 | -4.52 ± 50.68 | -29.92 ± 53.19 | 3.00 ± NA |
PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour PMG minus the Week 0 2-hour PMG.
| mg/dL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 20 | -2.9 ± 42.6 | 2.1 ± 72.1 | -6.8 ± 21.1 | 63.5 ± 171.8 |
PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour PMG minus the Week 0 2-hour PMG.
| mg/dL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in 2-hour PMG at Week 54 | -1.7 ± 21.3 | -16.8 ± 48.9 | -39.7 ± 32.3 | -28.0 ± NA |
2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.
| mg/dL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in 2-hour Incremental PMG at Week 20 | 1.5 ± 55.3 | 0.7 ± 35.9 | 0.8 ± 15.6 | 12.5 ± 98.3 |
2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.
| mg/dL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in 2-Hour Incremental PMG at Week 54 | -0.6 ± 64.6 | -26.6 ± 39.0 | -31.3 ± 34.8 | -32.0 ± NA |
This change from baseline reflects the Week 20 insulin minus the Week 0 insulin.
| mIU/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Insulin at Week 20 for Participants Not on Background Insulin | 1.59 ± 47.24 | -3.91 ± 22.31 | -7.25 ± 60.58 | -1.23 ± 20.55 |
This change from baseline reflects the Week 54 insulin minus the Week 0 insulin.
| mIU/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Insulin at Week 54 For Participants Not on Background Insulin | -9.65 ± 40.82 | -6.64 ± 32.01 | -20.50 ± 65.08 | -9.95 ± NA |
This change from baseline reflects the Week 20 proinsulin minus the Week 0 proinsulin.
| pmol/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Proinsulin at Week 20 For Participants Not on Background Insulin | 0.91 ± 81.88 | -10.88 ± 55.12 | 12.57 ± 36.98 | -1.33 ± 9.07 |
This change from baseline reflects the Week 54 proinsulin minus the Week 0 proinsulin.
| pmol/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Proinsulin at Week 54 For Participants Not on Background Insulin | -10.62 ± 67.54 | -16.13 ± 81.52 | -23.30 ± 42.36 | -0.50 ± NA |
Change from baseline was the Week 20 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.
| Ratio | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Proinsulin/Insulin Ratio at Week 20 for Participants Not on Background Insulin | 0.02 ± 0.22 | 0.02 ± 0.16 | -0.03 ± 0.10 | -0.19 ± 0.45 |
The change from baseline was Week 54 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.
| Ratio | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Proinsulin/Insulin Ratio at Week 54 For Participants Not on Background Insulin | 0.02 ± 0.23 | -0.03 ± 0.19 | -0.01 ± 0.06 | 0.02 ± NA |
HOMA-β = 20 × fasting insulin (in mcIU/mL) ÷ {\[FPG (in mg/dL)/18\] - 3.5}. The change from baseline was Week 20 HOMA-β minus the Week 0 HOMA-β.
| Percentage of Beta Cell Function | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Homeostatic Model Assessment of β-cell Function (HOMA-β) at Week 20 For Participants Not on Background Insulin | 15.72 ± 162.47 | -53.23 ± 296.23 | -1757.50 ± 4765.46 | -64.78 ± 126.65 |
HOMA-β = 20 × fasting insulin (in mcIU/mL) ÷ {\[FPG (in mg/dL)/18\] - 3.5}. This change from baseline was Week 54 HOMA-β minus the Week 0 HOMA-β.
| Percentage of Beta Cell Function | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in HOMA-β at Week 54 For Participants Not on Background Insulin | -41.15 ± 183.17 | -63.88 ± 339.74 | -1860.69 ± 4099.22 | -121.48 ± NA |
HOMA-IR = fasting insulin (in mcIU/mL) × FPG (in mg/dL) / (22.5×18). This change from baseline was Week 20 HOMA-IR minus the Week 0 HOMA-IR.
| Index of insulin resistance | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 20 For Participants Not on Background Insulin | -0.50 ± 31.62 | -0.86 ± 9.02 | -4.46 ± 34.65 | 2.58 ± 9.30 |
HOMA-IR = fasting insulin (in mcIU/mL) × FPG (in mg/dL) / (22.5×18). This change from baseline was Week 54 HOMA-IR minus the Week 0 HOMA-IR.
| Index of insulin resistance | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in HOMA-IR at Week 54 For Participants Not on Background Insulin | -6.13 ± 34.86 | -1.30 ± 15.31 | -15.18 ± 36.41 | -2.21 ± NA |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.
| mg*hr/dL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Glucose 3-Hour Total Area Under the Curve (AUC) at Week 20 | -49.3 ± 103.6 | 2.0 ± 190.0 | 18.6 ± 50.9 | 191.0 ± 434.2 |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.
| µIU*hr/mL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Insulin 3-hour AUC at Week 20 | -14.5 ± 128.0 | -32.8 ± 99.9 | 141.7 ± 206.1 | -145.6 ± 180.6 |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.
| ng*hr/mL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in C-peptide 3-Hour AUC at Week 20 | -1.8 ± 4.9 | -0.1 ± 3.3 | 5.9 ± 7.6 | -6.4 ± 7.1 |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin total AUC/glucose total AUC ratio minus the Week 0 insulin total AUC/glucose total AUC ratio.
| [µIU*hr/mL]/[mg*hr/dL] | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Insulin 3-Hour AUC/ Glucose 3-Hour AUC Ratio at Week 20 | 0.0 ± 0.3 | -0.1 ± 0.3 | 0.2 ± 0.4 | -0.2 ± 0.3 |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.
| mg*hr/dL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Glucose Excursion 3-Hour AUC at Week 20 | -43.5 ± 97.4 | 10.8 ± 58.6 | 39.8 ± 50.1 | 46.2 ± 201.9 |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.
| µIU*hr/mL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Insulin Excursion 3-Hour AUC at Week 20 | -12.4 ± 89.4 | -19.4 ± 93.6 | 87.5 ± 124.5 | -82.8 ± 93.4 |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.
| ng*hr/ml | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in C-peptide Excursion 3-Hour AUC at Week 20 | -1.1 ± 3.1 | -0.4 ± 4.4 | 4.1 ± 5.6 | -4.8 ± 5.2 |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.
| [μIU*hr/mL]/[mg*hr/dL] | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 20 | 2.2 ± 9.6 | 7.2 ± 17.5 | -2.5 ± 3.2 | 1.4 ± 2.2 |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.
| mg*hr/dL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Glucose 3-Hour AUC at Week 54 | -21.1 ± 47.7 | -36.0 ± 136.1 | -73.1 ± 95.8 | -63.3 ± NA |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.
| µIU*hr/mL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Insulin 3-Hour AUC at Week 54 | -43.2 ± 259.8 | -253.9 ± 282.7 | -37.8 ± 9.4 | -184.4 ± NA |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.
| ng*hr/ml | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in C-peptide 3-Hour AUC at Week 54 | -0.1 ± 5.7 | -6.1 ± 8.2 | 1.7 ± 1.0 | -8.9 ± NA |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC/glucose 3-hour AUC ratio minus the Week 0 insulin 3-hour AUC/glucose 3-hour AUC ratio.
| [μIU*hr/mL]/[mg*hr/dL] | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Insulin 3-Hour AUC/Glucose 3-Hour AUC Ratio at Week 54 | -0.1 ± 0.5 | -0.6 ± 0.8 | -0.0 ± 0.2 | -0.3 ± NA |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.
| mg*hr/dL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Glucose Excursion 3-Hour AUC at Week 54 | -30.7 ± 100.7 | -50.1 ± 79.5 | -49.0 ± 87.5 | -74.0 ± NA |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.
| µIU*hr/mL | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Insulin Excursion 3-Hour AUC at Week 54 | -103.8 ± 151.0 | -198.5 ± 263.0 | -40.2 ± 11.5 | -116.6 ± NA |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.
| ng*hr/ml | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in C-Peptide Excursion 3-Hour AUC at Week 54 | -1.8 ± 3.0 | -5.2 ± 8.8 | 0.9 ± 0.5 | -5.9 ± NA |
AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.
| [µIU*hr/mL]/[mg*hr/dL] | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 54 | 4.1 ± 13.1 | 3.7 ± 5.6 | -2.7 ± 4.3 | 1.4 ± NA |
The percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.
| Percentage of participants | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20 | 5.3 | 11.1 | 0.0 | 40.0 |
The percentage of participants who initiated glycemic rescue therapy prior to Week 54 was reported.
| Percentage of participants | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percentage of Participants Initiating Glycemic Rescue Therapy by Week 54 | 35.8 | 28.9 | 11.1 | 80.0 |
This change from baseline was Week 20 BMI minus the Week 0 BMI.
| kg/m^2 | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) at Week 20 | 0.0 ± 2.2 | -0.7 ± 1.9 | -0.8 ± 1.4 | -1.7 ± 2.8 |
This change from baseline was Week 54 BMI minus the Week 0 BMI.
| kg/m^2 | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in BMI at Week 54 | -0.4 ± 2.9 | -1.0 ± 2.9 | -0.6 ± 1.3 | -0.3 ± 1.6 |
The percent change from baseline in CD26 = (\[CD26 value at Week 20\] - \[baseline CD26 value\]) ÷ baseline CD26 value × 100.
| Percent Change | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 20 | 4.06 ± 19.25 | -1.78 ± 17.18 | 4.89 ± 1.90 | 14.57 ± 15.46 |
The percent change from baseline in CD26 = (\[CD26 value at Week 54\] - \[baseline CD26 value\]) ÷ baseline CD26 value × 100.
| Percent Change | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 54 | 4.74 ± 17.18 | 4.27 ± 18.24 | 12.63 ± 13.02 | -5.30 ± 4.19 |
Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.
| ng/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Calcitonin at Week 20 - Females | -0.1 ± 0.5 | -2.0 ± 11.7 | 0.0 ± 0.0 | 0.0 ± 0.0 |
Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.
| ng/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Calcitonin at Week 54 - Females | -1.0 ± 0.6 | -1.9 ± 12.1 | 0.0 ± 0.0 | 0.3 ± 0.4 |
Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.
| ng/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Calcitonin at Week 20 - Males | 0.2 ± 1.4 | -0.2 ± 0.6 | -1.6 ± 2.2 | 0.5 ± 0.6 |
Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.
| ng/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Calcitonin at Week 54 - Males | 0.1 ± 1.1 | -0.3 ± 0.9 | 0.0 ± NA | 1.4 ± 0.3 |
Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents
| nmol(BCE)/mmol(creatinine) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Urine N-terminal Cross-linking Telopeptide of Bone Collagen [u-NTx]/Creatinine Ratio at Week 20 - Females | -28.7 ± 120.9 | -41.2 ± 148.9 | -98.0 ± 153.0 | 12.7 ± 29.2 |
Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents
| nmol(BCE)/mmol(creatinine) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline u-NTx/Creatinine Ratio at Week 20 - Males | -30.9 ± 167.2 | -69.8 ± 162.1 | 62.0 ± NA | -29.0 ± 32.5 |
Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. Bone Collagen Equivalents
| nmol(BCE)/mmol(creatinine) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Females | -88.4 ± 102.6 | -61.2 ± 137.6 | -80.3 ± 208.5 | -17.0 ± 13.5 |
Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. All participants in the Metformin arm were missing baseline or Week 54 measurements. BCE = Bone Collagen Equivalents
| nmol(BCE)/mmol(creatinine) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Males | -78.2 ± 166.9 | -102.4 ± 267.7 | — | -30.0 ± NA |
Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.
| μg/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Females | -6.0 ± 13.7 | -4.2 ± 9.9 | -9.7 ± 7.7 | 10.7 ± 9.7 |
Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.
| μg/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Females | -20.0 ± 28.4 | -13.5 ± 18.1 | -14.9 ± 10.3 | -6.9 ± 9.2 |
Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.
| μg/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Males | -2.2 ± 21.6 | 0.1 ± 19.9 | -7.1 ± 0.2 | 4.7 ± 8.2 |
Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.
| μg/L | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Males | -16.2 ± 28.0 | -15.0 ± 27.0 | -1.3 ± NA | -15.3 ± 12.4 |
IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 20\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.
| Percent Change | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percent Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) at Week 20 - Females | 0.5 ± 21.9 | 11.0 ± 34.0 | -3.2 ± 14.9 | 41.4 ± 31.2 |
IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 54\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.
| Percent Change | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percent Change From Baseline in IGF-1 at Week 54 - Females | -1.5 ± 34.4 | 7.2 ± 57.6 | -11.9 ± 13.4 | -13.5 ± NA |
IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 20\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.
| Percent Change | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percent Change From Baseline in IGF-1 at Week 20 - Males | -2.7 ± 22.1 | 9.3 ± 29.6 | 7.6 ± 17.4 | 5.3 ± 16.2 |
IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 54\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.
| Percent Change | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percent Change From Baseline in IGF-1 at Week 54 - Males | -4.9 ± 33.5 | 29.6 ± 99.8 | 18.8 ± NA | -6.8 ± 22.1 |
IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 20\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.
| Percent Change | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percent Change From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) at Week 20 - Females | 3.5 ± 18.2 | 3.8 ± 13.8 | 8.4 ± 12.9 | -0.7 ± 24.1 |
IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 54\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.
| Percent Change | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percent Change From Baseline in IGF-BP3 at Week 54 - Females | 2.0 ± 16.7 | 4.5 ± 17.0 | 11.4 ± 17.4 | -13.4 ± 9.9 |
IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 20\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.
| Percent Change | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percent Change From Baseline in IGF-BP3 at Week 20 - Males | 5.6 ± 13.3 | 10.2 ± 18.6 | 3.3 ± 0.5 | 14.2 ± 50.6 |
IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 54\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.
| Percent Change | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Percent Change From Baseline in IGF-BP3 at Week 54 - Males | 5.4 ± 18.4 | 18.2 ± 43.1 | -2.9 ± NA | 22.5 ± 8.3 |
Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).
| cm/year | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Growth Velocity at Week 20 - Females | 3.2 ± 8.2 | 1.9 ± 2.7 | 5.0 ± 6.8 | 0.6 ± 1.6 |
Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).
| cm/year | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Growth Velocity at Week 54 - Females | 2.1 ± 3.7 | 1.2 ± 1.8 | 2.4 ± 2.9 | 0.7 ± 1.0 |
Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).
| cm/year | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Growth Velocity at Week 20 - Males | 2.6 ± 2.7 | 3.6 ± 3.2 | -1.0 ± 1.3 | 1.7 ± 2.4 |
Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).
| cm/year | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Growth Velocity at Week 54 - Males | 2.5 ± 2.5 | 2.8 ± 2.1 | 1.7 ± NA | 2.8 ± 4.0 |
Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from an X-ray of left hand and wrist.
| Ratio | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Skeletal Maturation at Week 20 - Females | 0.6 ± 1.9 | 0.4 ± 1.8 | 1.7 ± 2.3 | -0.8 ± 5.5 |
Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Placebo/Sitagliptin arm were missing baseline or Week 54 measurements.
| Ratio | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Skeletal Maturation at Week 54 - Females | 1.3 ± 1.1 | 1.0 ± 0.6 | 1.3 ± 2.2 | — |
Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist.
| Ratio | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Skeletal Maturation at Week 20 - Males | 1.6 ± 1.7 | 1.2 ± 1.1 | 0.4 ± NA | 2.4 ± NA |
Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Metformin and Placebo/Sitagliptin arms were missing baseline or Week 54 measurements.
| Ratio | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Skeletal Maturation at Week 54 - Males | 1.3 ± 0.9 | 1.3 ± 0.6 | — | — |
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 20 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia.
| Score on a scale | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Tanner Staging for Genitalia at Week 20 - Males | 0.3 ± 0.5 | 0.2 ± 0.4 | 0.0 ± NA | 0.5 ± 0.7 |
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 54 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia. All participants in the Metformin arm were missing baseline or Week 54 measurements.
| Score on a scale | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Tanner Staging for Genitalia at Week 54 - Males | 0.5 ± 0.6 | 0.6 ± 0.7 | — | 0.6 ± 0.7 |
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 20 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.
| Score on a Scale | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Tanner Staging for Breasts at Week 20 - Females | 0.2 ± 0.6 | 0.1 ± 0.3 | 0.2 ± 0.4 | 0.3 ± 0.6 |
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 54 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.
| Score on a Scale | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Tanner Staging for Breasts at Week 54 - Females | 0.5 ± 0.7 | 0.4 ± 0.6 | 0.5 ± 1.0 | 0.7 ± 0.6 |
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.
| Score on a scale | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Females | 0.1 ± 0.4 | 0.1 ± 0.3 | 0.2 ± 0.4 | 0.0 ± 0.0 |
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.
| Score on a scale | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Females | 0.5 ± 0.6 | 0.3 ± 0.5 | 0.8 ± 1.5 | 0.3 ± 0.6 |
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.
| Score on a scale | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Males | 0.3 ± 0.5 | 0.2 ± 0.4 | 0.0 ± NA | 0.5 ± 0.7 |
Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.
| Score on a scale | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Males | 0.5 ± 0.7 | 0.6 ± 0.5 | — | 0.5 ± 0.7 |
Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 20 dental assessments versus baseline dental assessments.
| Participants | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| 1. With ≥1 tooth with worsening in any category | 32 | 25 | 1 | 0 |
| 2. With ≥1 tooth with worsening fracture | 5 | 5 | 0 | 0 |
| 3. With ≥1 tooth with worsening discoloration | 29 | 23 | 0 | 0 |
| 4. With ≥1 tooth with worsening enamel defect | 7 | 4 | 1 | 0 |
Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 54 dental assessments versus baseline dental assessments.
| Participants | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| 1. With ≥1 tooth with worsening in any category | 49 | 50 | 2 | 0 |
| 2. With ≥1 tooth with worsening fracture | 13 | 15 | 1 | 0 |
| 3. With ≥1 tooth with worsening discoloration | 45 | 48 | 2 | 0 |
| 4. With ≥1 with worsening enamel defect | 13 | 13 | 1 | 0 |
Collected over SAEs and AEs: Up to approximately Week 56. Deaths: Up to approximately 42 months after randomization.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | 1/96 (1%) | 10/95 (10.5%) | 62/95 (65.3%) |
| Placebo/Metformin | 0/90 (0%) | 7/90 (7.8%) | 53/90 (58.9%) |
| Metformin | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| Placebo/Sitagliptin | 0/5 (0%) | 3/5 (60%) | 4/5 (80%) |
| Event | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| Blood glucose increasedInvestigations | 1/95 | 0/90 | 0/9 | 1/5 |
| Affect labilityPsychiatric disorders | 0/95 | 0/90 | 0/9 | 1/5 |
| NephrolithiasisRenal and urinary disorders | 0/95 | 0/90 | 0/9 | 1/5 |
| AppendicitisInfections and infestations | 0/95 | 1/90 | 1/9 | 0/5 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/95 | 0/90 | 0/9 | 0/5 |
| Dengue feverInfections and infestations | 0/95 | 1/90 | 0/9 | 0/5 |
| Gastroenteritis viralInfections and infestations | 0/95 | 1/90 | 0/9 | 0/5 |
| ConcussionInjury, poisoning and procedural complications | 0/95 | 1/90 | 0/9 | 0/5 |
| DehydrationMetabolism and nutrition disorders | 0/95 | 1/90 | 0/9 | 0/5 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/95 | 1/90 | 0/9 | 0/5 |
| Event | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 16/95 | 12/90 | 3/9 | 2/5 |
| DizzinessNervous system disorders | 3/95 | 2/90 | 0/9 | 2/5 |
| DiarrhoeaGastrointestinal disorders | 8/95 | 11/90 | 2/9 | 0/5 |
| HeadacheNervous system disorders | 9/95 | 13/90 | 2/9 | 1/5 |
| Eye painEye disorders | 0/95 | 0/90 | 0/9 | 1/5 |
| PertussisInfections and infestations | 0/95 | 0/90 | 0/9 | 1/5 |
| Upper respiratory tract infectionInfections and infestations | 12/95 | 12/90 | 1/9 | 1/5 |
| Viral infectionInfections and infestations | 0/95 | 0/90 | 0/9 | 1/5 |
| Alanine aminotransferase increasedInvestigations | 4/95 | 3/90 | 0/9 | 1/5 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/95 | 1/90 | 1/9 | 1/5 |
The analysis population consisted of all randomized and treated participants.
| Age, Continuous(years) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|
| Mean | 14.3 ± 2.0 | 13.7 ± 1.9 | 13.3 ± 3.0 | 15.0 ± 1.6 | 14.0 ± 2.0 |
| Age, Customized(Participants) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|
| In utero | 0 | 0 | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 | 0 | 0 |
| Children (2-11 years) | 11 | 11 | 3 | 0 | 25 |
| Adolescents (12-17 years) | 84 | 79 | 6 | 5 | 174 |
| Adults (18-64 years) | 0 | 0 | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|
| Female | 54 | 58 | 6 | 3 | 121 |
| Male | 41 | 32 | 3 | 2 | 78 |
| Ethnicity (NIH/OMB)(Participants) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 36 | 33 | 2 | 2 | 73 |
| Not Hispanic or Latino | 53 | 54 | 5 | 3 | 115 |
| Unknown or Not Reported | 6 | 3 | 2 | 0 | 11 |
| Race (NIH/OMB)(Participants) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 6 | 9 | 0 | 0 | 15 |
| Asian | 13 | 14 | 1 | 2 | 30 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 2 | 1 | 0 | 11 |
| White | 48 | 47 | 6 | 3 | 104 |
| More than one race | 20 | 18 | 1 | 0 | 39 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Glycated Hemoglobin (A1C)(Percentage) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|
| Mean | 7.43 ± 1.02 | 7.56 ± 1.08 | 7.43 ± 1.07 | 8.02 ± 0.75 | 7.50 ± 1.04 |
| Fasting Plasma Glucose(mg/dL) | Sitagliptin | Placebo/Metformin | Metformin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|
| Mean | 138.4 ± 47.2 | 138.6 ± 42.8 | 134.6 ± 59.1 | 142.2 ± 38.7 | 138.6 ± 44.7 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2012 to primary completion in Oct 2019, 91 months.
Results were first posted in Dec 2020, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 91 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin